Inhalation Drug Delivery News

  1. CEPI Partners With Intravacc To Develop An Intranasal, Broadly Protective Betacoronavirus Vaccine 10/6/2022

    CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced the latest funding award under CEPI's US$200m program to advance the development of vaccines that provide broad protection against SARS-CoV-2 (including its variants) and other Betacoronaviruses.

  2. Nutriband With Kindeva Drug Delivery Demonstrate Enhanced Abuse-Deterrent Characteristics For Aversa™ Fentanyl 10/4/2022

    Studies at Kindeva Drug Delivery have demonstrated that Nutriband’s proprietary transdermal aversive coating can be manufactured using standard commercial transdermal manufacturing processes, which is critical to the success of the product development program.

  3. Transpire Bio Announces Second Agreement With Recipharm For The Development Of Two Additional Inhaled Medicines 9/29/2022

    Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a second definitive agreement with Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).

  4. Intravacc Announces Additional Favorable Preclinical And Toxicology Data For Avacc 10®, An Intranasal SARS-CoV-2 Candidate Vaccine 9/12/2022

    Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine

  5. Hovione Expands Drug Product Offering With A New Manufacturing Line Dedicated To Continuous Tableting 9/6/2022

    Hovione, the leader in spray drying and particle engineering, announced today that it has expanded its continuous manufacturing offering and services. A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal

  6. CDMO Hovione Expands With New Manufacturing Line For Continuous Tableting Operations 9/6/2022

    Hovione, the leader in spray drying and particle engineering, announced today that it has expanded its continuous manufacturing offering and services. A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal.

  7. Zerion Pharma And Insud Pharma Announce Collaboration To Develop Dispersome Formulations Of Marketed Drug Products 8/29/2022

    The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop and commercialize drug products applying ZERION’s solubility enhancing Dispersome technology

  8. Zerion Pharma And Hovione Extend Partnership To Cover Use Of The Dispersome® Technology Platform In Nutraceuticals 8/23/2022

    Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field

  9. Piramal Pharma Solutions Holds Grand Opening Ceremony For New API Plant At Aurora, Canada Manufacturing Site 7/12/2022

    Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), held a Grand Opening to celebrate the official inauguration of a new active pharmaceutical ingredient (API) plant at the company's site in Aurora, Ontario.

  10. Naobios Delivers FluGen Inc's M2SR Influenza Vaccine Candidate For Upcoming Clinical Trials 6/21/2022

    Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors, today announces it has successfully completed the development and GMP manufacturing of the clinical batch of M2SR influenza vaccine-candidate for FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases